Back to trial

NCT03025035

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Version 19 to 20 · Yuan Yuan

Patch inspector

Version 19 to 20

18 operations 5 path groups ctgov_internal_history
ClinicalTrials.gov
Severity is deterministic uncalibrated triage metadata, not validated review priority. Operation-level severity is inferred from deterministic path rules. Rule matches shown per operation are approximate previews (they skip the pipeline's suppression passes); the authoritative classification is the stored event record.
Plain-language summary

Manual review pending.

Rules fired
enrollment_count_changeenrollment_type_change
Value signals
[
  {
    "path": "/protocolSection/designModule/enrollmentInfo/count",
    "signal": "enrollment_count_change_ge_20pct",
    "category": "enrollment_change",
    "severity": "high",
    "new_value": 14,
    "old_value": 20,
    "pct_change": 0.3
  },
  {
    "paths": [
      "/protocolSection/outcomesModule/primaryOutcomes/0/measure",
      "/protocolSection/outcomesModule/secondaryOutcomes/0/measure",
      "/protocolSection/outcomesModule/secondaryOutcomes/1/measure",
      "/protocolSection/outcomesModule/secondaryOutcomes/2/measure",
      "/protocolSection/outcomesModule/secondaryOutcomes/3/measure"
    ],
    "signal": "results_reconciliation_outcome_suppression",
    "category": "results_reconciliation",
    "severity": "low"
  }
]
Provenance
Source
ctgov_internal_history
Fetched
2026-06-18 18:58:42+00
Raw hash
c1ec0d2f1a5948700226b311b4f11323cbea5bd1b93c770df1d333296c67ccec
Payload
Source URL
Primary outcomes Outcome measures that define the trial's primary evidence target. Triage: Critical 1 ops
replace /protocolSection/outcomesModule/primaryOutcomes/0/measure
Triage: Critical
Primary Outcome Change Operation 10
Matched rules
  • primary_outcome_any_change Any add/remove/replace under primary outcome measures is critical review priority.
Before
Overall response rate (ORR) per RECIST1.1
After
Overall Response Rate (ORR) Per RECIST1.1
Design Trial model, phase, allocation, masking, arms, or interventions. Triage: High 2 ops
replace /protocolSection/designModule/enrollmentInfo/count
Triage: High
Enrollment Change Operation 8
Matched rules
  • enrollment_count_change Enrollment count changes can signal scope or feasibility shifts.
Before
20
After
14
replace /protocolSection/designModule/enrollmentInfo/type
Triage: High
Enrollment Change Operation 9
Matched rules
  • enrollment_type_change Enrollment type changes from anticipated to actual or similar are high review priority.
Before
ESTIMATED
After
ACTUAL
Secondary outcomes Additional endpoints and outcome descriptions. Triage: High 4 ops
replace /protocolSection/outcomesModule/secondaryOutcomes/0/measure
Triage: High
Secondary Outcome Change Operation 11
Matched rules
  • secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.
Before
Progression free survival (PFS), per RECIST 1.1
After
Progression Free Survival (PFS), Per RECIST 1.1
replace /protocolSection/outcomesModule/secondaryOutcomes/1/measure
Triage: High
Secondary Outcome Change Operation 12
Matched rules
  • secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.
Before
Overall survival (OS)
After
Overall Survival (OS)
replace /protocolSection/outcomesModule/secondaryOutcomes/2/measure
Triage: High
Secondary Outcome Change Operation 13
Matched rules
  • secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.
Before
Clinical Benefit Rate (CBR = CR+PR+SD) per RECIST 1.1
After
Clinical Benefit Rate (CBR = CR+PR+SD) Per RECIST 1.1
replace /protocolSection/outcomesModule/secondaryOutcomes/3/measure
Triage: High
Secondary Outcome Change Operation 14
Matched rules
  • secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.
Before
Duration of Response (DOR) for Complete Response (CR) and Partial Response (PR) per RECIST 1.1
After
Duration of Response (DOR) for Complete Response (CR) and Partial Response (PR) Per RECIST 1.1
Other registry fields Changes outside the current high-signal rule families. Triage: Uncategorized 8 ops
replace /protocolSection/statusModule/statusVerifiedDate
Triage: Uncategorized
Uncategorized Operation 3
Before
2024-12
After
2025-04
replace /protocolSection/statusModule/lastUpdateSubmitDate
Triage: Uncategorized
Uncategorized Operation 4
Before
2024-12-06
After
2025-04-29
replace /protocolSection/statusModule/lastUpdatePostDateStruct/date
Triage: Uncategorized
Uncategorized Operation 5
Before
2024-12-11
After
2025-05-09
add /protocolSection/statusModule/resultsFirstSubmitDate
Triage: Uncategorized
Uncategorized Operation 6
After
2025-04-29
replace /hasResults
Triage: Uncategorized
Uncategorized Operation 15
Before
false
After
true
add /resultsSection
Triage: Uncategorized
Uncategorized Operation 16
After
{
  "moreInfoModule": {
    "pointOfContact": {
      "email": "yuan.yuan@cshs.org",
      "phone": "3108888680",
      "title": "Yuan Yuan, MD, PhD",
      "organization": "Cedars-Sinai Medical Center"
    },
    "certainAgreement": {
      "piSponsorEmployee": true
    }
  },
  "adverseEventsModule": {
    "timeFrame": "Adverse events are collected for up to two years of total study participation.",
    "eventGroups": [
      {
        "id": "EG000",
        "title": "Pembrolizumab + Olaparib",
        "description": "<p>This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.</p><p>Pembrolizumab: Pembrolizumab IV solution administered on Day 1 of each 3-week cycle</p><p>Olaparib: Olaparib administered orally twice a day</p>",
        "otherNumAtRisk": 11,
        "deathsNumAtRisk": 11,
        "otherNumAffected": 11,
        "seriousNumAtRisk": 11,
        "deathsNumAffected": 1,
        "seriousNumAffected": 0
      }
    ],
    "otherEvents": [
      {
        "term": "Anemia Hemoglobin",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 14,
            "numAffected": 6
          }
        ],
        "organSystem": "Blood and lymphatic system disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Anorexia",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 2,
            "numAffected": 2
          }
        ],
        "organSystem": "Metabolism and nutrition disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Anorexia",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Gastrointestinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Anxiety",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Psychiatric disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Back Pain",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 3,
            "numAffected": 3
          }
        ],
        "organSystem": "Musculoskeletal and connective tissue disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Bloating",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Gastrointestinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Blood Bilirubin Increased",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Blood and lymphatic system disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Concentration Impairment",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Nervous system disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Constipation",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 3,
            "numAffected": 3
          }
        ],
        "organSystem": "Gastrointestinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Cough",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Respiratory, thoracic and mediastinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Creatinine increased",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Renal and urinary disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Diarrhea",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 3,
            "numAffected": 3
          }
        ],
        "organSystem": "Gastrointestinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Dizziness",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 2,
            "numAffected": 2
          }
        ],
        "organSystem": "Nervous system disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Dysgeusia",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 2,
            "numAffected": 2
          }
        ],
        "organSystem": "Nervous system disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Dysgeusia",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Gastrointestinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Edema Limbs",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 2,
            "numAffected": 2
          }
        ],
        "organSystem": "General disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Eye disorders - Other",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Eye disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Eye pain",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Eye disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Eyelid Function Disorder",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Eye disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Fall",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 2,
            "numAffected": 2
          }
        ],
        "organSystem": "Injury, poisoning and procedural complications",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Fatigue",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 4,
            "numAffected": 4
          }
        ],
        "organSystem": "General disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Flank Pain",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Musculoskeletal and connective tissue disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Gastroesophagael Reflux",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Gastrointestinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Headache",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 4,
            "numAffected": 4
          }
        ],
        "organSystem": "Nervous system disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Hypercalcemia",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Metabolism and nutrition disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Hyperthyroidism",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 2,
            "numAffected": 2
          }
        ],
        "organSystem": "Endocrine disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Insomnia",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Psychiatric disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Joint Range of Motion Decreased",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Musculoskeletal and connective tissue disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Malaise",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "General disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Mucositis Oral",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Gastrointestinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Myalgia",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Musculoskeletal and connective tissue disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Nausea",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 8,
            "numAffected": 8
          }
        ],
        "organSystem": "Gastrointestinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Non-Cardiac Chest Pain",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 2,
            "numAffected": 1
          }
        ],
        "organSystem": "General disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Oral Pain",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Gastrointestinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Other- Pain at Biopsy Site",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "General disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Other- Tinnitus",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Ear and labyrinth disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Other- Muscle Cramps",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Musculoskeletal and connective tissue disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Pain",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 2,
            "numAffected": 2
          }
        ],
        "organSystem": "General disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Pain in Extremity",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Musculoskeletal and connective tissue disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Palpitations",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Cardiac disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Paresthesia",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Cardiac disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Peripheral Sensory Neuropathy",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Nervous system disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Postnasal Drip",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Respiratory, thoracic and mediastinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Stomach Pain",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Gastrointestinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Thromboembolic Event",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Vascular disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Vomiting",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 4,
            "numAffected": 3
          }
        ],
        "organSystem": "Gastrointestinal disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "White blood cell decreased",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "Injury, poisoning and procedural complications",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      },
      {
        "term": "Other- Injection Site Pain (Intermittent)",
        "stats": [
          {
            "groupId": "EG000",
            "numAtRisk": 11,
            "numEvents": 1,
            "numAffected": 1
          }
        ],
        "organSystem": "General disorders",
        "assessmentType": "SYSTEMATIC_ASSESSMENT"
      }
    ],
    "frequencyThreshold": "0",
    "allCauseMortalityReviewUnit": {
      "resetReasons": [
        "Information in other parts of the record suggests that adverse events were collected that are not reported here."
      ]
    }
  },
  "outcomeMeasuresModule": {
    "outcomeMeasures": [
      {
        "type": "PRIMARY",
        "title": "Overall Response Rate (ORR) Per RECIST1.1",
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              {
                "value": "11",
                "groupId": "OG000"
              }
            ]
          }
        ],
        "groups": [
          {
            "id": "OG000",
            "title": "Pembrolizumab + Olaparib",
            "description": "<p>This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.</p><p>Pembrolizumab: Pembrolizumab IV solution administered on Day 1 of each 3-week cycle</p><p>Olaparib: Olaparib administered orally twice a day</p>"
          }
        ],
        "classes": [
          {
            "categories": [
              {
                "measurements": [
                  {
                    "value": "7",
                    "groupId": "OG000"
                  }
                ]
              }
            ]
          }
        ],
        "paramType": "COUNT_OF_PARTICIPANTS",
        "timeFrame": "Up to 2 years",
        "description": "Defined as complete or partial response per RECIST 1.1 criteria with assessment every 9 weeks during the first year and while on the study drug, and every 12 weeks thereafter.",
        "unitOfMeasure": "Participants",
        "reportingStatus": "POSTED"
      },
      {
        "type": "SECONDARY",
        "title": "Progression Free Survival (PFS), Per RECIST 1.1",
        "timeFrame": "Up to 2 years",
        "description": "As measured by RECIST 1.1, in patients progressing after 1st line therapy",
        "reportingStatus": "NOT_POSTED",
        "denomUnitsSelected": "Participants"
      },
      {
        "type": "SECONDARY",
        "title": "Overall Survival (OS)",
        "timeFrame": "Up to 2 years",
        "description": "Calculated in months from the start of treatment to the date of death from any cause",
        "reportingStatus": "NOT_POSTED",
        "denomUnitsSelected": "Participants"
      },
      {
        "type": "SECONDARY",
        "title": "Clinical Benefit Rate (CBR = CR+PR+SD) Per RECIST 1.1",
        "timeFrame": "Up to 2 years",
        "description": "As measured by RECIST 1.1, in patients progressing after 1st line therapy",
        "reportingStatus": "NOT_POSTED",
        "denomUnitsSelected": "Participants"
      },
      {
        "type": "SECONDARY",
        "title": "Duration of Response (DOR) for Complete Response (CR) and Partial Response (PR) Per RECIST 1.1",
        "timeFrame": "Up to 2 years",
        "description": "As measured by RECIST 1.1, in patients progressing after 1st line therapy",
        "reportingStatus": "NOT_POSTED",
        "denomUnitsSelected": "Participants"
      }
    ]
  },
  "participantFlowModule": {
    "groups": [
      {
        "id": "FG000",
        "title": "Pembrolizumab + Olaparib",
        "description": "<p>This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.</p><p>Pembrolizumab: Pembrolizumab IV solution administered on Day 1 of each 3-week cycle</p><p>Olaparib: Olaparib administered orally twice a day</p>"
      }
    ],
    "periods": [
      {
        "title": "Overall Study",
        "milestones": [
          {
            "type": "STARTED",
            "achievements": [
              {
                "groupId": "FG000",
                "numSubjects": "14"
              }
            ]
          },
          {
            "type": "COMPLETED",
            "achievements": [
              {
                "groupId": "FG000",
                "numSubjects": "11"
              }
            ]
          },
          {
            "type": "NOT COMPLETED",
            "achievements": [
              {
                "groupId": "FG000",
                "numSubjects": "3"
              }
            ]
          }
        ],
        "dropWithdraws": [
          {
            "type": "Death",
            "reasons": [
              {
                "groupId": "FG000",
                "numSubjects": "2"
              }
            ]
          },
          {
            "type": "Disease progression and was taken off study. Only received pembrolizumab &amp; is not evaluable.",
            "reasons": [
              {
                "groupId": "FG000",
                "numSubjects": "1"
              }
            ]
          }
        ]
      }
    ]
  },
  "baselineCharacteristicsModule": {
    "denoms": [
      {
        "units": "Participants",
        "counts": [
          {
            "value": "11",
            "groupId": "BG000"
          }
        ]
      }
    ],
    "groups": [
      {
        "id": "BG000",
        "title": "Pembrolizumab + Olaparib",
        "description": "<p>This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.</p><p>Pembrolizumab: Pembrolizumab IV solution administered on Day 1 of each 3-week cycle</p><p>Olaparib: Olaparib administered orally twice a day</p>"
      }
    ],
    "measures": [
      {
        "title": "Age, Categorical",
        "classes": [
          {
            "categories": [
              {
                "title": "&lt;=18 years",
                "measurements": [
                  {
                    "value": "0",
                    "groupId": "BG000"
                  }
                ]
              },
              {
                "title": "Between 18 and 65 years",
                "measurements": [
                  {
                    "value": "7",
                    "groupId": "BG000"
                  }
                ]
              },
              {
                "title": "&gt;=65 years",
                "measurements": [
                  {
                    "value": "4",
                    "groupId": "BG000"
                  }
                ]
              }
            ]
          }
        ],
        "paramType": "COUNT_OF_PARTICIPANTS",
        "unitOfMeasure": "Participants"
      },
      {
        "title": "Age, Continuous",
        "classes": [
          {
            "categories": [
              {
                "measurements": [
                  {
                    "value": "54.45455",
                    "spread": "13.09476",
                    "groupId": "BG000"
                  }
                ]
              }
            ]
          }
        ],
        "paramType": "MEAN",
        "unitOfMeasure": "years",
        "dispersionType": "STANDARD_DEVIATION"
      },
      {
        "title": "Sex: Female, Male",
        "classes": [
          {
            "categories": [
              {
                "title": "Female",
                "measurements": [
                  {
                    "value": "11",
                    "groupId": "BG000"
                  }
                ]
              },
              {
                "title": "Male",
                "measurements": [
                  {
                    "value": "0",
                    "groupId": "BG000"
                  }
                ]
              }
            ]
          }
        ],
        "paramType": "COUNT_OF_PARTICIPANTS",
        "unitOfMeasure": "Participants"
      },
      {
        "title": "Ethnicity (NIH&#x2F;OMB)",
        "classes": [
          {
            "categories": [
              {
                "title": "Hispanic or Latino",
                "measurements": [
                  {
                    "value": "0",
                    "groupId": "BG000"
                  }
                ]
              },
              {
                "title": "Not Hispanic or Latino",
                "measurements": [
                  {
                    "value": "11",
                    "groupId": "BG000"
                  }
                ]
              },
              {
                "title": "Unknown or Not Reported",
                "measurements": [
                  {
                    "value": "0",
                    "groupId": "BG000"
                  }
                ]
              }
            ]
          }
        ],
        "paramType": "COUNT_OF_PARTICIPANTS",
        "unitOfMeasure": "Participants"
      },
      {
        "title": "Race (NIH&#x2F;OMB)",
        "classes": [
          {
            "categories": [
              {
                "title": "American Indian or Alaska Native",
                "measurements": [
                  {
                    "value": "0",
                    "groupId": "BG000"
                  }
                ]
              },
              {
                "title": "Asian",
                "measurements": [
                  {
                    "value": "1",
                    "groupId": "BG000"
                  }
                ]
              },
              {
                "title": "Native Hawaiian or Other Pacific Islander",
                "measurements": [
                  {
                    "value": "0",
                    "groupId": "BG000"
                  }
                ]
              },
              {
                "title": "Black or African American",
                "measurements": [
                  {
                    "value": "1",
                    "groupId": "BG000"
                  }
                ]
              },
              {
                "title": "White",
                "measurements": [
                  {
                    "value": "8",
                    "groupId": "BG000"
                  }
                ]
              },
              {
                "title": "More than one race",
                "measurements": [
                  {
                    "value": "1",
                    "groupId": "BG000"
                  }
                ]
              },
              {
                "title": "Unknown or Not Reported",
                "measurements": [
                  {
                    "value": "0",
                    "groupId": "BG000"
                  }
                ]
              }
            ]
          }
        ],
        "paramType": "COUNT_OF_PARTICIPANTS",
        "unitOfMeasure": "Participants"
      },
      {
        "title": "Region of Enrollment",
        "classes": [
          {
            "title": "United States",
            "categories": [
              {
                "measurements": [
                  {
                    "value": "11",
                    "groupId": "BG000"
                  }
                ]
              }
            ]
          }
        ],
        "paramType": "NUMBER",
        "unitOfMeasure": "participants"
      }
    ]
  }
}
add /annotationSection
Triage: Uncategorized
Uncategorized Operation 17
After
{
  "annotationModule": {
    "unpostedAnnotation": {
      "unpostedEvents": [
        {
          "date": "2025-05-08",
          "type": "RESET"
        }
      ],
      "unpostedResponsibleParty": "Yuan Yuan, Director, Breast Oncology, Cedars-Sinai Medical Center"
    }
  }
}
add /documentSection
Triage: Uncategorized
Uncategorized Operation 18
After
{
  "largeDocumentModule": {
    "largeDocs": [
      {
        "date": "2023-12-05",
        "size": 955275,
        "label": "Study Protocol and Statistical Analysis Plan",
        "hasIcf": false,
        "hasSap": true,
        "filename": "Prot_SAP_000.pdf",
        "typeAbbrev": "Prot_SAP",
        "uploadDate": "2025-04-29T15:55",
        "hasProtocol": true
      },
      {
        "date": "2024-04-08",
        "size": 278677,
        "label": "Informed Consent Form",
        "hasIcf": true,
        "hasSap": false,
        "filename": "ICF_001.pdf",
        "typeAbbrev": "ICF",
        "uploadDate": "2025-04-29T15:57",
        "hasProtocol": false
      }
    ]
  }
}
Sponsor and administrative fields Sponsor, collaborator, oversight, or registry maintenance changes. Triage: Uncategorized 3 ops
replace /protocolSection/identificationModule/briefTitle
Triage: Uncategorized
Uncategorized Operation 1
Before
Pembrolizumab in Combination with Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
After
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
replace /protocolSection/identificationModule/officialTitle
Triage: Uncategorized
Uncategorized Operation 2
Before
Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Combination with PARP Inhibition with Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancers
After
Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition With Pembrolizumab in Combination With PARP Inhibition With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancers
remove /protocolSection/oversightModule/isUsExport
Triage: Uncategorized
Uncategorized Operation 7
Before
false
Raw JSON Patch 
[
  {
    "op": "replace",
    "path": "/protocolSection/identificationModule/briefTitle",
    "value": "Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer"
  },
  {
    "op": "replace",
    "path": "/protocolSection/identificationModule/officialTitle",
    "value": "Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition With Pembrolizumab in Combination With PARP Inhibition With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancers"
  },
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/statusVerifiedDate",
    "value": "2025-04"
  },
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/lastUpdateSubmitDate",
    "value": "2025-04-29"
  },
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/lastUpdatePostDateStruct/date",
    "value": "2025-05-09"
  },
  {
    "op": "add",
    "path": "/protocolSection/statusModule/resultsFirstSubmitDate",
    "value": "2025-04-29"
  },
  {
    "op": "remove",
    "path": "/protocolSection/oversightModule/isUsExport"
  },
  {
    "op": "replace",
    "path": "/protocolSection/designModule/enrollmentInfo/count",
    "value": 14
  },
  {
    "op": "replace",
    "path": "/protocolSection/designModule/enrollmentInfo/type",
    "value": "ACTUAL"
  },
  {
    "op": "replace",
    "path": "/protocolSection/outcomesModule/primaryOutcomes/0/measure",
    "value": "Overall Response Rate (ORR) Per RECIST1.1"
  },
  {
    "op": "replace",
    "path": "/protocolSection/outcomesModule/secondaryOutcomes/0/measure",
    "value": "Progression Free Survival (PFS), Per RECIST 1.1"
  },
  {
    "op": "replace",
    "path": "/protocolSection/outcomesModule/secondaryOutcomes/1/measure",
    "value": "Overall Survival (OS)"
  },
  {
    "op": "replace",
    "path": "/protocolSection/outcomesModule/secondaryOutcomes/2/measure",
    "value": "Clinical Benefit Rate (CBR = CR+PR+SD) Per RECIST 1.1"
  },
  {
    "op": "replace",
    "path": "/protocolSection/outcomesModule/secondaryOutcomes/3/measure",
    "value": "Duration of Response (DOR) for Complete Response (CR) and Partial Response (PR) Per RECIST 1.1"
  },
  {
    "op": "replace",
    "path": "/hasResults",
    "value": true
  },
  {
    "op": "add",
    "path": "/resultsSection",
    "value": {
      "moreInfoModule": {
        "pointOfContact": {
          "email": "yuan.yuan@cshs.org",
          "phone": "3108888680",
          "title": "Yuan Yuan, MD, PhD",
          "organization": "Cedars-Sinai Medical Center"
        },
        "certainAgreement": {
          "piSponsorEmployee": true
        }
      },
      "adverseEventsModule": {
        "timeFrame": "Adverse events are collected for up to two years of total study participation.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "Pembrolizumab + Olaparib",
            "description": "<p>This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.</p><p>Pembrolizumab: Pembrolizumab IV solution administered on Day 1 of each 3-week cycle</p><p>Olaparib: Olaparib administered orally twice a day</p>",
            "otherNumAtRisk": 11,
            "deathsNumAtRisk": 11,
            "otherNumAffected": 11,
            "seriousNumAtRisk": 11,
            "deathsNumAffected": 1,
            "seriousNumAffected": 0
          }
        ],
        "otherEvents": [
          {
            "term": "Anemia Hemoglobin",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 14,
                "numAffected": 6
              }
            ],
            "organSystem": "Blood and lymphatic system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Anorexia",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 2,
                "numAffected": 2
              }
            ],
            "organSystem": "Metabolism and nutrition disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Anorexia",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Anxiety",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Psychiatric disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Back Pain",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 3,
                "numAffected": 3
              }
            ],
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Bloating",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Blood Bilirubin Increased",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Blood and lymphatic system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Concentration Impairment",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Nervous system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Constipation",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 3,
                "numAffected": 3
              }
            ],
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Cough",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Respiratory, thoracic and mediastinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Creatinine increased",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Renal and urinary disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Diarrhea",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 3,
                "numAffected": 3
              }
            ],
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Dizziness",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 2,
                "numAffected": 2
              }
            ],
            "organSystem": "Nervous system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Dysgeusia",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 2,
                "numAffected": 2
              }
            ],
            "organSystem": "Nervous system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Dysgeusia",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Edema Limbs",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 2,
                "numAffected": 2
              }
            ],
            "organSystem": "General disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Eye disorders - Other",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Eye disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Eye pain",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Eye disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Eyelid Function Disorder",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Eye disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Fall",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 2,
                "numAffected": 2
              }
            ],
            "organSystem": "Injury, poisoning and procedural complications",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Fatigue",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 4,
                "numAffected": 4
              }
            ],
            "organSystem": "General disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Flank Pain",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Gastroesophagael Reflux",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Headache",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 4,
                "numAffected": 4
              }
            ],
            "organSystem": "Nervous system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Hypercalcemia",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Metabolism and nutrition disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Hyperthyroidism",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 2,
                "numAffected": 2
              }
            ],
            "organSystem": "Endocrine disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Insomnia",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Psychiatric disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Joint Range of Motion Decreased",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Malaise",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "General disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Mucositis Oral",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Myalgia",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Nausea",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 8,
                "numAffected": 8
              }
            ],
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Non-Cardiac Chest Pain",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 2,
                "numAffected": 1
              }
            ],
            "organSystem": "General disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Oral Pain",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Other- Pain at Biopsy Site",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "General disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Other- Tinnitus",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Ear and labyrinth disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Other- Muscle Cramps",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Pain",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 2,
                "numAffected": 2
              }
            ],
            "organSystem": "General disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Pain in Extremity",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Palpitations",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Cardiac disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Paresthesia",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Cardiac disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Peripheral Sensory Neuropathy",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Nervous system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Postnasal Drip",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Respiratory, thoracic and mediastinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Stomach Pain",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Thromboembolic Event",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Vascular disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Vomiting",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 4,
                "numAffected": 3
              }
            ],
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "White blood cell decreased",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "Injury, poisoning and procedural complications",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          },
          {
            "term": "Other- Injection Site Pain (Intermittent)",
            "stats": [
              {
                "groupId": "EG000",
                "numAtRisk": 11,
                "numEvents": 1,
                "numAffected": 1
              }
            ],
            "organSystem": "General disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT"
          }
        ],
        "frequencyThreshold": "0",
        "allCauseMortalityReviewUnit": {
          "resetReasons": [
            "Information in other parts of the record suggests that adverse events were collected that are not reported here."
          ]
        }
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Overall Response Rate (ORR) Per RECIST1.1",
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "value": "11",
                    "groupId": "OG000"
                  }
                ]
              }
            ],
            "groups": [
              {
                "id": "OG000",
                "title": "Pembrolizumab + Olaparib",
                "description": "<p>This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.</p><p>Pembrolizumab: Pembrolizumab IV solution administered on Day 1 of each 3-week cycle</p><p>Olaparib: Olaparib administered orally twice a day</p>"
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "value": "7",
                        "groupId": "OG000"
                      }
                    ]
                  }
                ]
              }
            ],
            "paramType": "COUNT_OF_PARTICIPANTS",
            "timeFrame": "Up to 2 years",
            "description": "Defined as complete or partial response per RECIST 1.1 criteria with assessment every 9 weeks during the first year and while on the study drug, and every 12 weeks thereafter.",
            "unitOfMeasure": "Participants",
            "reportingStatus": "POSTED"
          },
          {
            "type": "SECONDARY",
            "title": "Progression Free Survival (PFS), Per RECIST 1.1",
            "timeFrame": "Up to 2 years",
            "description": "As measured by RECIST 1.1, in patients progressing after 1st line therapy",
            "reportingStatus": "NOT_POSTED",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Overall Survival (OS)",
            "timeFrame": "Up to 2 years",
            "description": "Calculated in months from the start of treatment to the date of death from any cause",
            "reportingStatus": "NOT_POSTED",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Clinical Benefit Rate (CBR = CR+PR+SD) Per RECIST 1.1",
            "timeFrame": "Up to 2 years",
            "description": "As measured by RECIST 1.1, in patients progressing after 1st line therapy",
            "reportingStatus": "NOT_POSTED",
            "denomUnitsSelected": "Participants"
          },
          {
            "type": "SECONDARY",
            "title": "Duration of Response (DOR) for Complete Response (CR) and Partial Response (PR) Per RECIST 1.1",
            "timeFrame": "Up to 2 years",
            "description": "As measured by RECIST 1.1, in patients progressing after 1st line therapy",
            "reportingStatus": "NOT_POSTED",
            "denomUnitsSelected": "Participants"
          }
        ]
      },
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "Pembrolizumab + Olaparib",
            "description": "<p>This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.</p><p>Pembrolizumab: Pembrolizumab IV solution administered on Day 1 of each 3-week cycle</p><p>Olaparib: Olaparib administered orally twice a day</p>"
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "14"
                  }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "11"
                  }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "3"
                  }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Death",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "2"
                  }
                ]
              },
              {
                "type": "Disease progression and was taken off study. Only received pembrolizumab &amp; is not evaluable.",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "1"
                  }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              {
                "value": "11",
                "groupId": "BG000"
              }
            ]
          }
        ],
        "groups": [
          {
            "id": "BG000",
            "title": "Pembrolizumab + Olaparib",
            "description": "<p>This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib in 20 subjects with advanced BRCA mutation or HDR-defect associated breast cancer having progressed through at least a standard first line therapy.</p><p>Pembrolizumab: Pembrolizumab IV solution administered on Day 1 of each 3-week cycle</p><p>Olaparib: Olaparib administered orally twice a day</p>"
          }
        ],
        "measures": [
          {
            "title": "Age, Categorical",
            "classes": [
              {
                "categories": [
                  {
                    "title": "&lt;=18 years",
                    "measurements": [
                      {
                        "value": "0",
                        "groupId": "BG000"
                      }
                    ]
                  },
                  {
                    "title": "Between 18 and 65 years",
                    "measurements": [
                      {
                        "value": "7",
                        "groupId": "BG000"
                      }
                    ]
                  },
                  {
                    "title": "&gt;=65 years",
                    "measurements": [
                      {
                        "value": "4",
                        "groupId": "BG000"
                      }
                    ]
                  }
                ]
              }
            ],
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants"
          },
          {
            "title": "Age, Continuous",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "value": "54.45455",
                        "spread": "13.09476",
                        "groupId": "BG000"
                      }
                    ]
                  }
                ]
              }
            ],
            "paramType": "MEAN",
            "unitOfMeasure": "years",
            "dispersionType": "STANDARD_DEVIATION"
          },
          {
            "title": "Sex: Female, Male",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "value": "11",
                        "groupId": "BG000"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "value": "0",
                        "groupId": "BG000"
                      }
                    ]
                  }
                ]
              }
            ],
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants"
          },
          {
            "title": "Ethnicity (NIH&#x2F;OMB)",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      {
                        "value": "0",
                        "groupId": "BG000"
                      }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      {
                        "value": "11",
                        "groupId": "BG000"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "value": "0",
                        "groupId": "BG000"
                      }
                    ]
                  }
                ]
              }
            ],
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants"
          },
          {
            "title": "Race (NIH&#x2F;OMB)",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      {
                        "value": "0",
                        "groupId": "BG000"
                      }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      {
                        "value": "1",
                        "groupId": "BG000"
                      }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      {
                        "value": "0",
                        "groupId": "BG000"
                      }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      {
                        "value": "1",
                        "groupId": "BG000"
                      }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      {
                        "value": "8",
                        "groupId": "BG000"
                      }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      {
                        "value": "1",
                        "groupId": "BG000"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "value": "0",
                        "groupId": "BG000"
                      }
                    ]
                  }
                ]
              }
            ],
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants"
          },
          {
            "title": "Region of Enrollment",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      {
                        "value": "11",
                        "groupId": "BG000"
                      }
                    ]
                  }
                ]
              }
            ],
            "paramType": "NUMBER",
            "unitOfMeasure": "participants"
          }
        ]
      }
    }
  },
  {
    "op": "add",
    "path": "/annotationSection",
    "value": {
      "annotationModule": {
        "unpostedAnnotation": {
          "unpostedEvents": [
            {
              "date": "2025-05-08",
              "type": "RESET"
            }
          ],
          "unpostedResponsibleParty": "Yuan Yuan, Director, Breast Oncology, Cedars-Sinai Medical Center"
        }
      }
    }
  },
  {
    "op": "add",
    "path": "/documentSection",
    "value": {
      "largeDocumentModule": {
        "largeDocs": [
          {
            "date": "2023-12-05",
            "size": 955275,
            "label": "Study Protocol and Statistical Analysis Plan",
            "hasIcf": false,
            "hasSap": true,
            "filename": "Prot_SAP_000.pdf",
            "typeAbbrev": "Prot_SAP",
            "uploadDate": "2025-04-29T15:55",
            "hasProtocol": true
          },
          {
            "date": "2024-04-08",
            "size": 278677,
            "label": "Informed Consent Form",
            "hasIcf": true,
            "hasSap": false,
            "filename": "ICF_001.pdf",
            "typeAbbrev": "ICF",
            "uploadDate": "2025-04-29T15:57",
            "hasProtocol": false
          }
        ]
      }
    }
  }
]